Why wouldn't PAB be a takeover target??? Amgen $113 a share PAB .059 cents per share. Amgen 17000 employees PAB a dozen employees maybe Amgen $17bn income a year PAB not an awful lot of income otherwise management might have found another way to raise $12m. In any game one would think to go from research and development to production or manufacture the cost would a bucket load more than $12m.What would the cost be just to recruit the personnel for production and meet salaries. I would also suspect the research centre at Friedrich-Bergius-Ring 15 97076 Würzburg would not be satisfactory for manufacture (Its a research centre)and another premises would be required. Would equipment has to be acquired to sustain production? Does PAB have a distribution network? Does PAB have a supply network for the acquisition of consumables?
Amgen this year took over Onyx Pharmaceuticals Inc for a lazy $10bn at $125 a share. Compare Amgen's income of 17bn to Johnson and Johnson 67bn and the thirteen major pharmaceutical companies in between. What is it going to cost those 15 companies if they don't win Partry's seven year patents as well as the R&D for the other products. As far as I can see Its a no brainer for the majors. All's fair in luv and war. I really hope there is a fair dinkum scrap for Patry's
PAB Price at posting:
5.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)